ICER's Review Of Rebate Reform, At A Glance
The Institute for Clinical and Economic Review has weighed in on the pros and cons of rebate reform, surveying an assortment of payers, pharmacy benefit managers and pharmaceutical companies on alternative rebate models and their potential impact.
You may also be interested in...
US biotech expands 2017 collaboration with Alnylam and inks collaboration with WuXi. Plus deals involving AbbVie, Allergan, Amazon, Thermo Fisher, Qiagen, Boehringer Ingelheim, Trutino, Taiho, Arcus, Eisai, Fuji Yakuhin, Hikma, Glenmark, Hanmi, GC, Bayer, GW.
Research published in JAMA shows that the pharmaceutical industry outpaces other industries in the S&P 500 on several measures of profitability.
Mylan’s full year 2019 earnings report was its last as an independent company, so the focus was on the coming merger with Pfizer’s Upjohn and growth prospects for the new company, Viatris.